PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Journal of Movement Disorders10.14802/jmd.1505920169114-19Mechanism of Anti-α-Synuclein ImmunotherapyJun Sung Lee, Seung-Jae Leehttp://e-jmd.org/upload/jmd-15059.pdf, http://e-jmd.org/journal/view.php?doi=10.14802/jmd.15059, http://www.e-jmd.org/upload/jmd-15059.pdf
Journal for ImmunoTherapy of Cancer10.1186/s40425-019-0786-7201971Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanismJaina M. Patel, Zhihua Cui, Zhi-Fa Wen, Catherine T. Dinh, Hong-Ming Huhttp://link.springer.com/content/pdf/10.1186/s40425-019-0786-7.pdf, http://link.springer.com/article/10.1186/s40425-019-0786-7/fulltext.html, http://link.springer.com/content/pdf/10.1186/s40425-019-0786-7.pdf
Immunotherapy and Biomarkers in Neurodegenerative Disorders10.1007/978-1-4939-3560-4_5201663-72Immunotherapy Against α-Synuclein PathologyElvira Valera, Eliezer Masliahhttp://link.springer.com/content/pdf/10.1007/978-1-4939-3560-4_5
Immunotherapy and Biomarkers in Neurodegenerative Disorders10.1007/978-1-4939-3560-4_6201673-83Extracellular α-Synuclein as a Target for ImmunotherapyJun Sung Lee, Seung-Jae Leehttp://link.springer.com/content/pdf/10.1007/978-1-4939-3560-4_6
Journal for ImmunoTherapy of Cancer10.1186/2051-1426-1-s1-p7720131S1Indoleamine 2,3-dioxygenase is a critical resistance mechanism in anti-tumor T cell immunotherapy targeting CTLA-4Rikke B Holmgaard, Dmitriy Zamarin, David H Munn, Jedd D Wolchok, James P Allisonhttp://link.springer.com/content/pdf/10.1186/2051-1426-1-S1-P77.pdf, http://link.springer.com/article/10.1186/2051-1426-1-S1-P77/fulltext.html, http://link.springer.com/content/pdf/10.1186/2051-1426-1-S1-P77.pdf
Journal of Parkinson's Disease10.3233/jpd-150630201553413-424Immunotherapy in Parkinson’s Disease: Micromanaging Alpha-Synuclein AggregationSonia George, Patrik Brundinhttps://content.iospress.com/download?id=10.3233/JPD-150630
Molecular Therapy10.1016/j.ymthe.2005.07.486200511S365943. Anti-alpha-Synuclein scFv Studyhttps://api.elsevier.com/content/article/PII:S1525001605012098?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1525001605012098?httpAccept=text/plain
Journal for ImmunoTherapy of Cancer10.1136/jitc-2019-000186corr1202082e000186corr1Correction: On the mechanism of anti-CD39 immune checkpoint therapyhttps://syndication.highwire.org/content/doi/10.1136/jitc-2019-000186corr1
Cancer Immunology, Immunotherapy10.1007/s00262-009-0792-62009593341-353Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccinationMohamed Labib Salem, David J. Colehttp://link.springer.com/content/pdf/10.1007/s00262-009-0792-6.pdf, http://link.springer.com/article/10.1007/s00262-009-0792-6/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00262-009-0792-6
Acta Neuropathologica Communications10.1186/s40478-016-0410-8201751Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathyBrian Spencer, Elvira Valera, Edward Rockenstein, Cassia Overk, Michael Mante, Anthony Adame, Wagner Zago, Peter Seubert, Robin Barbour, Dale Schenk, Dora Games, Robert A. Rissman, Eliezer Masliahhttp://link.springer.com/content/pdf/10.1186/s40478-016-0410-8.pdf, http://link.springer.com/article/10.1186/s40478-016-0410-8/fulltext.html, http://link.springer.com/content/pdf/10.1186/s40478-016-0410-8.pdf